COLUMVI Patent Protection Prolonged: FDA's Usual Suspects
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for COLUMVI, a human biological product, so its patent can be extended. This helps the company behind COLUMVI get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for future market competition and innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patent-Extension Step Opened for COLUMVI
The FDA has determined the regulatory review period for COLUMVI, a human biological product, so the company can submit applications to the U.S. Patent and Trademark Office to seek a patent extension that claims that product. This notice documents that formal step in the patent-extension process.
Timing Update Relevant to Market Competition
The FDA's determination affects timing for COLUMVI's patent-extension process, which the notice says gives the company extra time to protect the invention before generic versions can appear. If you work in drug patents, pharmaceuticals, or healthcare, this timing update is relevant to future market competition and innovation related to that product.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in